Full-Time
Product Operations Manager
Antibody Discovery
Posted on 9/3/2025
Integral Molecular
51-200 employees
Antibody discovery and vaccine development platform
No salary listed
Philadelphia, PA, USA
Hybrid
 Biology & Biotech (5) |
|---|
| , , , , |
- Bachelor’s or Master’s in a biological science (PhD applicants interested in transitioning to marketing are welcome)
- At least 2 years of experience in product management, marketing, sales operations, or scientific commercialization
- Strong understanding of antibodies and their applications as research reagents and/or therapeutics
- Strong written and verbal communicator, able to translate technical content into market-facing strategy
- Comfortable using tools like e-commerce platforms, CRMs, Excel/Sheets, or basic analytics dashboards
- Curious, analytical, and organized, eager to manage complexity and solve customer problems
- A proactive collaborator who thrives in fast-paced, team-driven environments
- Oversee e-commerce operations by ensuring accurate product listings, addressing platform issues, processing manual orders, and ensuring accurate order handling
- Manage customer communication and sales support by responding to inquiries, scheduling calls, and overseeing quotes and orders for both catalog and custom antibody products
- Support lead generation and outreach efforts by identifying new leads through publication research and targeted outreach and email campaigns in collaboration with marketing
- Leverage customer insights, market trends, and competitive analysis to shape product strategy and uncover growth opportunities
- Coordinate with scientific, legal, finance, and operations teams to support timely and accurate product and project delivery
- Maintain internal documentation and recommend improvements to workflows and system tools
- Support product planning by analyzing customer feedback and contributing to pricing, positioning, and roadmap development.
Integral Molecular focuses on antibodies, viruses, and membrane proteins, offering technologies, platforms, and services to help researchers develop therapies for hard-to-treat diseases. Its tools support antibody discovery, safety profiling of biotherapeutics, vaccine development, and protein engineering. The company differentiates itself through a research-driven emphasis on membrane proteins and viral targets, providing specialized platforms and collaborations for complex targets. Its goal is to speed up the creation of effective therapies by applying its expertise and technologies to challenging biological targets.
Company Size
51-200
Company Stage
Grant
Total Funding
$10.6M
Headquarters
Philadelphia, Pennsylvania
Founded
2001
Simplify's Take
What believers are saying
- FDA accepted MPA qualification plan February 2025, advancing DDT status.
- NIH awarded $2.7M November 2024 for MPA commercialization readiness.
- CTIM-76 bispecific antibody dosed in Phase 1 trial March 2025.
What critics are saying
- FDA rejects MPA Full Qualification Package submitted late 2025.
- Context Therapeutics halts CTIM-76 Phase 1 trial due to safety signals.
- Large CROs qualify competing specificity platforms within 12 months.
What makes Integral Molecular unique
- Membrane Proteome Array screens 6,000 native membrane proteins for specificity.
- Paratope-PLUS CDR-scanning supports USPTO-compliant antibody genus claims.
- Ready Reporter Virus kit enables 10x faster, BSL-free neutralization testing.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 2%2 year growth
↓ -1%Integral Molecular, a leader in antibody discovery and characterisation against membrane proteins, has appointed Cheryl Paes as vice president of commercial strategy. Paes will lead strategic initiatives to support commercial growth of the company's technology platforms serving biotechnology and pharmaceutical industries. Paes brings over 15 years of experience in biotechnology and life sciences, previously holding leadership roles at Meridian Life Science, Center for Breakthrough Medicines, Clarivate Analytics and Zimmer Biomet. She has also served in scientific and business advisory roles at Integral Molecular. The appointment comes as Integral Molecular expands its antibody characterisation technologies portfolio, including a recently launched CDR-Scanning service. The company's Membrane Proteome Array platform, used for therapeutic specificity testing, is progressing towards FDA qualification.
Follow its DDT qualification journey. * March 13, 2026 * admin Welcome to Specificity Insights, its blog about current developments in antibody specificity testing! Over the coming months, Integral Molecular, Inc.'ll be releasing a multi-part series about specificity testing with the Membrane Proteome Array (MPA) and its journey to qualify the MPA as a Drug Development Tool (DDT) through the FDA's ISTAND program. Through this series, you'll gain access to detailed information about its regulatory-ready specificity testing service and an inside look at the ISTAND qualification process. Integral Molecular, Inc.'ll also share broader news about specificity testing and developments at Integral Molecular. What's this series about? In 2021, Integral Molecular, Inc. began working toward qualifying its MPA specificity testing platform as a DDT under the FDA's ISTAND program. Qualification is a rigorous process. It has involved extensive discussions with the FDA about its technology, processes, and data, along with implementing their suggestions for enhancements. In late 2025, Integral Molecular, Inc. submitted its Full Qualification Package (FQP), the final set of information the FDA needs to make their decision. The FQP is a comprehensive document loaded with valuable information. While some details remain confidential - like trade secrets and project data - much of it can be shared. Integral Molecular, Inc.'ll be breaking down much of that content through this blog series, providing detailed insights into the questions the FDA asked Integral Molecular, Inc. and its responses. In a few weeks, Integral Molecular, Inc.'ll also release an ebook with even more information. This document will be useful for anyone seeking details about its specificity testing platform. And for those working toward qualifying their own DDT, it will provide insights into the FDA's thinking. Why pursue FDA qualification? For anyone considering qualifying a tool through ISTAND, Integral Molecular, Inc. highly recommend it. The experience has been invaluable. FDA review and input have transformed an already unmatched specificity testing platform into a tool that's even more robust, reproducible, scalable, and well-documented. To date, DDTs are under-utilized in drug development and rarely included in IND filings. To increase DDT adoption, the FDA is actively encouraging others to qualify their tools, and they are incentivizing drug developers to use these tools and include the resulting data in their regulatory submissions. DDTs, they believe, will help get better treatments to patients faster. Looking ahead: What's coming in this series. This series will cover a broad range of topics, including: Why current specificity testing methods fall short What the FDA qualification process looks like from the inside What Integral Molecular, Inc. learned from screening 2,000+ biotherapeutics The quality systems behind regulatory-grade testing How to interpret and use specificity data for decision-making ...and much more
10x faster virus neutralization testing with launch of Integral Molecular's Ready Reporter Virus(TM) kit. News provided by. PHILADELPHIA, Oct. 14, 2025 /PRNewswire/ - Integral Molecular, a leader in developing innovative tools for antiviral research, announces the launch of its Ready Reporter Virus(TM)(RRV) neutralization assay kit. This automation-compatible, safe assay assesses the effectiveness of vaccines and therapeutic antibodies and is set to transform how virus neutralization testing is performed. While conventional assays can take up to a week, the RRV kit delivers results in under 4 hours - 10 times faster than current standards. Learn more about RRVs, designed for high-throughput, automatable virus neutralization testing Conventional neutralization assays are labor intensive, requiring live pathogenic virus, specialized biosafety facilities, cultivation of cells under sterile conditions, and often manual counting of results. These barriers make testing impossible for most laboratories worldwide. In contrast, RRVs do not replicate or cause disease and do not require cell culture, making this assay accessible to all scientists. RRV kits come with thaw-and-mix reagents and use simple workflows ideal for automation, a key consideration for scientists who need to screen hundreds or even thousands of samples. Integral Molecular is the industry leader in providing viral particles to the vaccine industry, including its catalog of 100+ pseudotyped Reporter Virus Particles (RVPs) and Influenza TiterSafe(TM) Particles, a non-infectious alternative to the hemagglutination assay. RRVs expand this portfolio, giving scientists a powerful new way to perform rapid, safe virus neutralization experiments. RRVs are non-pathogenic, non-replicative virus-based particles that display authentic native viral proteins on their surface. Like live viruses, RRVs enter human cells through natural receptor interactions, providing biologically relevant neutralization data for therapeutic candidates. The RRV kit supplies live target cells preloaded with a dye that provides a quantitative readout immediately upon virus entry, so an end user just needs to thaw and mix the supplied reagents to assess virus infection. * Serum testing from humans or animals for vaccine-induced neutralization * Neutralization testing and lot-release for therapeutic antibodies * Public health applications including disease surveillance "Integral Molecular has long been committed to delivering safe, reliable tools that expand the ability of labs to conduct antiviral research critical for vaccine development," said Benjamin Doranz, PhD, CEO of Integral Molecular. "With RRVs, we are making neutralization testing not just faster, but also simpler, cost-effective, and more accessible for scientists who need robust, automatable assays without the burden of cell culture." RRV kits are currently available for viruses including influenza, SARS-CoV-2, and VSV. Kits are manufactured under ISO 9001-certified quality processes and can be customized for additional viruses or variants of interest. RRVs will be launched in a presentation by Christina Go, PhD, at the World Vaccine Congress this week in Amsterdam. About Integral Molecular Integral Molecular (virology.integralmolecular.com) is the industry leader in creating transformative technologies that advance the discovery of therapeutics against difficult protein targets. With 20+ years of experience focused on viruses, antibodies, and membrane proteins, Integral Molecular's technologies have been integrated into the drug discovery pipelines of over 600 biotech and pharmaceutical companies to help discover new therapies for viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses, as well as chronic diseases such as cancer, diabetes, and autoimmune disorders. Follow Integral Molecular on LinkedIn Press Contact Integral Molecular Soma Banik, PhD, Director of Public Relations 215-966-6061 SOURCE Integral Molecular
PHILADELPHIA, May 21, 2025 /PRNewswire/ -- Integral Molecular, a founding member of Philadelphia's biotechnology hub, has been recognized as a 2025 Top Workplace by the Philadelphia Inquirer. This honor is based entirely on employee feedback and benchmarking against national standards, gathered through a confidential survey.See the full list of Top Workplaces named by the Philadelphia Inquirer"We are honored to be recognized as a 2025 Top Workplace in Philadelphia," said Sharon Willis, PhD, Co-founder of Integral Molecular. "This award reflects the collaborative and mission-driven culture we have built together, where people are supported to thrive in their career. Our company's growth is based on continuing to hire remarkable people."Integral Molecular's success is rooted in its commitment to people and its supportive culture.Employee Development and a People First Culture: A supportive work environment where individual and team accomplishments are celebrated.A supportive work environment where individual and team accomplishments are celebrated. Community Partnerships: Strong connections with local organizations for recruiting, training, and retaining homegrown talent.Strong connections with local organizations for recruiting, training, and retaining homegrown talent. Biotechnology Leadership: Active participation in regional initiatives such as the Keystone Life Sciences Collaborative, promoting the expansion of the Pennsylvania life sciences ecosystem.This recognition follows a year of notable achievements for the company
Technology aligns with new USPTO guidance for writing antibody patent claims and enables antibody engineering for novel intellectual propertyPHILADELPHIA, March 11, 2025 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery and protein engineering, has launched a new technology-based service to strengthen antibody patent claims in response to recent changes in U.S. patent guidelines. Paratope-PLUS™ CDR-scanning uses high-throughput mutagenesis to support antibody patenting strategies and novel claim sets. Integral Molecular's CDR-scanning strategy is described in the February 2025 issue of Nature Biotechnology1.Learn how Paratope-PLUS™ CDR-scanning can protect antibody intellectual propertyParatope-PLUS™ involves mutating each residue of an antibody's CDRs (Complementarity Determining Regions) to all 19 other amino acids, identifying every variant that retains or enhances function. This approach broadly defines antibody 'genus' claims around a common structural feature (the paratope, the antibody residues that make direct contact with the target). Importantly, this fulfills U.S